Accuray Incorporated (0H8I.L)
USD 1.36
(1.15%)
USD 1.36
(1.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 446.55 Million USD | -0.24% |
| 2022 | 447.6 Million USD | 4.12% |
| 2021 | 429.9 Million USD | 8.48% |
| 2020 | 396.28 Million USD | 3.49% |
| 2019 | 382.92 Million USD | -8.56% |
| 2018 | 418.78 Million USD | 3.43% |
| 2017 | 404.89 Million USD | 5.6% |
| 2016 | 383.41 Million USD | -3.86% |
| 2015 | 398.8 Million USD | 5.0% |
| 2014 | 379.8 Million USD | 2.81% |
| 2013 | 369.41 Million USD | 16.91% |
| 2012 | 315.97 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 FY | 446.55 Million USD | -0.24% |
| 2023 Q2 | 107.23 Million USD | 3.22% |
| 2023 Q3 | 101.13 Million USD | -5.69% |
| 2023 Q4 | 134.28 Million USD | 32.79% |
| 2023 Q1 | 103.89 Million USD | -12.17% |
| 2022 Q4 | 118.29 Million USD | 0.2% |
| 2022 FY | 447.6 Million USD | 4.12% |
| 2022 Q3 | 118.06 Million USD | 2.88% |
| 2022 Q2 | 114.76 Million USD | 18.93% |
| 2022 Q1 | 96.49 Million USD | -12.3% |
| 2021 Q1 | 107.44 Million USD | -3.15% |
| 2021 Q2 | 116.27 Million USD | 8.22% |
| 2021 Q3 | 96.16 Million USD | -17.29% |
| 2021 Q4 | 110.02 Million USD | 14.41% |
| 2021 FY | 429.9 Million USD | 8.48% |
| 2020 Q3 | 102.56 Million USD | 5.24% |
| 2020 Q1 | 85.33 Million USD | -10.16% |
| 2020 Q4 | 110.93 Million USD | 8.16% |
| 2020 Q2 | 97.45 Million USD | 14.21% |
| 2020 FY | 396.28 Million USD | 3.49% |
| 2019 Q4 | 94.97 Million USD | -4.59% |
| 2019 Q1 | 89.57 Million USD | -23.71% |
| 2019 Q2 | 98.82 Million USD | 10.33% |
| 2019 FY | 382.92 Million USD | -8.56% |
| 2019 Q3 | 99.54 Million USD | 0.73% |
| 2018 Q4 | 117.41 Million USD | 13.75% |
| 2018 Q3 | 103.22 Million USD | 0.88% |
| 2018 Q2 | 102.31 Million USD | 6.77% |
| 2018 Q1 | 95.82 Million USD | -15.78% |
| 2018 FY | 418.78 Million USD | 3.43% |
| 2017 Q1 | 90.95 Million USD | -18.86% |
| 2017 FY | 404.89 Million USD | 5.6% |
| 2017 Q4 | 113.78 Million USD | 13.98% |
| 2017 Q3 | 99.83 Million USD | -0.5% |
| 2017 Q2 | 100.32 Million USD | 10.31% |
| 2016 Q4 | 112.09 Million USD | 15.19% |
| 2016 Q3 | 97.31 Million USD | 11.21% |
| 2016 Q2 | 87.5 Million USD | 1.15% |
| 2016 Q1 | 86.5 Million USD | -8.92% |
| 2016 FY | 383.41 Million USD | -3.86% |
| 2015 Q4 | 94.97 Million USD | -9.79% |
| 2015 Q1 | 89.63 Million USD | -11.91% |
| 2015 Q3 | 105.28 Million USD | -3.33% |
| 2015 Q2 | 108.91 Million USD | 21.51% |
| 2015 FY | 398.8 Million USD | 5.0% |
| 2014 FY | 379.8 Million USD | 2.81% |
| 2014 Q4 | 101.75 Million USD | 4.34% |
| 2014 Q1 | 82.38 Million USD | -19.23% |
| 2014 Q3 | 97.51 Million USD | -0.65% |
| 2014 Q2 | 98.15 Million USD | 19.15% |
| 2013 Q1 | 76.64 Million USD | -9.73% |
| 2013 Q3 | 97.14 Million USD | 3.75% |
| 2013 Q4 | 102 Million USD | 5.0% |
| 2013 FY | 369.41 Million USD | 16.91% |
| 2013 Q2 | 93.63 Million USD | 22.17% |
| 2012 Q4 | 84.9 Million USD | 20.35% |
| 2012 Q3 | 70.54 Million USD | -9.3% |
| 2012 Q2 | 77.77 Million USD | 0.0% |
| 2012 FY | 315.97 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Phreesia, Inc. | 356.29 Million USD | -25.33% |
| Align Technology, Inc. | 3.86 Billion USD | 88.438% |
| Elevance Health Inc. | 171.34 Billion USD | 99.739% |
| AxoGen, Inc. | 159.01 Million USD | -180.828% |
| Boston Scientific Corporation | 14.24 Billion USD | 96.864% |
| CVS Health Corporation | 357.77 Billion USD | 99.875% |
| Cardinal Health, Inc. | 226.82 Billion USD | 99.803% |
| Centene Corporation | 141.26 Billion USD | 99.684% |
| DaVita Inc. | 12.14 Billion USD | 96.322% |
| HCA Healthcare, Inc. | 64.96 Billion USD | 99.313% |
| Hologic, Inc. | 4.03 Billion USD | 88.92% |
| Humana Inc. | 106.37 Billion USD | 99.58% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 87.802% |
| Laboratory Corporation of America Holdings | 12.16 Billion USD | 96.328% |
| Masimo Corporation | 2.04 Billion USD | 78.197% |
| McKesson Corporation | 308.95 Billion USD | 99.855% |
| Patterson Companies, Inc. | 6.56 Billion USD | 93.201% |
| Quest Diagnostics Incorporated | 9.25 Billion USD | 95.173% |
| ResMed Inc. | 4.68 Billion USD | 90.469% |
| Henry Schein, Inc. | 12.33 Billion USD | 96.381% |
| Teladoc Health, Inc. | 2.6 Billion USD | 82.841% |
| Universal Health Services, Inc. | 14.28 Billion USD | 96.873% |
| Veeva Systems Inc. | 2.36 Billion USD | 81.108% |
| Baxter International Inc. | 14.81 Billion USD | 96.985% |
| Becton, Dickinson and Company | 19.37 Billion USD | 97.695% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 93.732% |
| Danaher Corporation | 23.89 Billion USD | 98.131% |
| Stryker Corporation | 20.49 Billion USD | 97.821% |
| Medtronic plc | 32.36 Billion USD | 98.62% |